Library — CHDR

Search

Filter

Safety, reactogenicity and immunogenicity of an intranasal seasonal influenza vaccine adjuvanted with gram-positive matrix (GEM) particles (FluGEM): A randomized, double-blind, controlled, ascending dose study in healthy adults and elderly.

van der Plas JL, Haijema BJ, Leenhouts K, Paul Zoeteweij J, Burggraaf J, Kamerling IMC

Vaccine, 2024 May

View publication
Fourth Controlled Human Infection Model (CHIM) meeting - CHIMs in endemic countries, May 22-23, 2023.

Kapulu M, Manda-Taylor L, Balasingam S, Means G, Ayiro Malungu M, Bejon P, Chi PC, Chiu C, Church EC, Correa-Oliveira R, Day N, Durbin A, Egesa M, Emerson C, Jambo K, Mathur R, Metzger W, Mumba N, Nazziwa W, Olotu A, Rodgers J, Sinyiza F, Talaat K, Kamerling I, Weller C, Baay M, Neels P

Biologicals : journal of the International Association of Biological Standardization, 2024 Feb

View publication
Regulatory workshop on challenge strain development and GMP manufacture - A stakeholder meeting report.

Corti N, Chiu C, Cox RJ, Demont C, Devaster JM, Engelhardt OG, Gorringe A, Hassan K, Hoefnagel M, Kamerling I, Krut O, Lane C, Liebers R, Luke C, Van Molle W, Morel S, Neels P, Roestenberg M, Rubbrecht M, Klaas Smits W, Stoughton D, Talaat K, Vehreschild MJGT, Wildfire A, Meln I, Olesen OF

Biologicals : journal of the International Association of Biological Standardization, 2024 Feb

View publication
Immunogenicity and reactogenicity of intradermal mRNA-1273 SARS-CoV-2 vaccination: a non-inferiority, randomized-controlled trial.

Prins MLM, Roozen GVT, Pothast CR, Huisman W, van Binnendijk R, den Hartog G, Kuiper VP, Prins C, Janse JJ, Lamers OAC, Koopman JPR, Kruithof AC, Kamerling IMC, Dijkland RC, de Kroon AC, Azimi S, Feltkamp MCW, Kuijer M, Jochems SP, Heemskerk MHM, Rosendaal FR, Roestenberg M, Visser LG, Roukens AHE

NPJ vaccines, 2024 Jan; 9(1):1

View publication
Safety and Immunogenicity of Intradermal Fractional Dose Administration of the mRNA-1273 Vaccine: A Proof-of-Concept Study.

Roozen GVT, Prins MLM, van Binnendijk R, den Hartog G, Kuiper VP, Prins C, Janse JJ, Kruithof AC, Feltkamp MCW, Kuijer M, Rosendaal FR, Roestenberg M, Visser LG, Roukens AHE

Annals of internal medicine, 2022 Oct

View publication
Viral clearance, pharmacokinetics and tolerability of ensovibep in patients with mild to moderate COVID-19: A phase 2a, open-label, single-dose escalation study.

Prins MLM, van der Plas JL, Vissers MFJM, Berends CL, Tresch G, Soergel M, Fernández E, van den Berge N, Duijsings D, Zitt C, Stavropoulou V, Zimmermann M, Drake RF, Burggraaf J, Groeneveld GH, Kamerling IMC

British journal of clinical pharmacology, 2022 Oct

View publication
Accelerating vaccine trial conduct in a pandemic with a hot spot-based inclusion strategy using trial and epidemic simulation.

van der Plas JL, van Esdonk MJ, Kamerling IMC, Cohen AF

Clinical and translational science, 2021 Jul

View publication
Assessment of risks associated with SARS-CoV-2 experimental human infection studies.

Kuiper VP, Rosendaal FR, Kamerling IMC, Visser LG, Roestenberg M

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020 Nov

View publication
How to expedite early-phase SARS-CoV-2 vaccine trials in pandemic setting-A practical perspective

Johan L van der Plas, Meta Roestenberg, Adam F Cohen, Ingrid M C Kamerling

Br J Clin Pharmacol, 2020 Sep

View publication

«
1
2
3
»